UCB: creating value for patien ts Company Overview Oct. 2017
UCB: reinventing itself, leveraging a solid heritage 2 1928: Emmanuel Janssen establishes UCB in Brussels 1972: A new stateof-the-art R&D center in Brainel Alleud, Belgium 1990s: approval of Keppra, a novel anti-epileptic 2006: UCB acquires German pharma company Schwarz Pharma Combine leadership in antibody research & chemistry expertise to better treat severe diseases 1936: UCB enters the United States 1952: UCB discovers Atarax U.S. license awarded to Pfizer 1980s: UCB registers its novel antihistamine Zyrtec 2004: UCB acquires British biotech company Celltech Launch of Cimzia, Vimpat & Neupro Launch of a new anti-epileptic 1928 1936 1952 1972 1980s 1990s 2004 2006 2008-2010 2016 Today Chemical Group Primary Care Pharma Specialty Bio-pharma
UCB: creating value for patients Bringing solutions to people living with neurological or immunological diseases 3 Key facts and figures 2016: Revenue: 4.2 billion rebitda: 1031 million More than 7500 employees globally Operations in ~40 countries R&D Spend: 24% of revenue Listed on Euronext
A global and diverse workforce 4 73 NATIONALITIES 50/50 MEN/WOMEN FY 2016 figures
3 core medicines for patients with severe diseases 5 Rheumatoid arthritis Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Axial spondyloarthritis (AxSpA) Crohn s disease Epilepsy Parkinson s disease Restless legs syndrome
Briviact (brivaracetam) 6 Our new anti-epileptic drug Quick facts Approved in Europe (Jan. 2016) and U.S. (Feb. 2016) as adjunctive therapy Received monotherapy label in the U.S. (Sep. 2017) Available in 12 countries Reached more than 13.000 patients * worldwide Expected peak sales of at least 400 million ** * FY 2016 ** By 2026
Other key products 7 Keppra (levetiracetam) Epilepsy adjunctive therapy (also in monotherapy in Europe) Sold as E Keppra in Japan Keppra XR (levetiracetam Extended-release tablets) Epilepsy adjunctive therapy U.S. only Zyrtec (cetirizine HCl) Seasonal allergic rhinitis Xyzal (levocetirizine dihydrochloride) Allergies and chronic idiopatic urticaria
Drug Development timelines Compound Attrition Rates Production Scales 8 Lab Scale Pilot Scale Industrial Scale Early R&D 2-4Y Pre- Clinical 1Y Phase I Phase II Phase III Approval Market 1-2Y 2Y 2-3Y 1-2Y Total:9-12Y Compound Attrition 20 13 6 2 1
9 R&D investors in Europe The 2016 EU Industrial scoreboard by R&D intensity % (top 60) 26,0 24,0 22,0 20,0 18,0 16,0 14,0 12,0 http://iri.jrc.ec.europa.eu/scoreboard16.html
10 R&D Investors Belgium (Millions ) 1.000 900 800 700 600 500 400 300 200 100 0 http://iri.jrc.ec.europa.eu/scoreboard16.html
A promising pipeline for differentiating solutions Evenity TM (romosozumab) osteoporosis UCB0942 (PPSI) highly drug resistant epilepsy dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus bimekizumab (IL17 A/F) various skin and arthritis indications Phase 1 Phase 2 Phase 3 Filing Phase 2a results: Q1 2017 Phase 2b results: H2 2018 Partner: Biogen Phase 2b results: Q3 2017 / Q3 2018 Partner: Amgen 11 bimekizumab add-on to Cimzia rheumatoid arthritis seletalisib (PI3K delta inhibitor) immunology indications UCB7665 (anti-fcrn) immunology indications UCB1332 Parkinson s disease UCB4144 / VR942 asthma UCB6673 immunology indications UCB3491 epilepsy UCB7858 immunology indications Phase 2a results: Q2 2017 Phase 2a results: Q4 2017 Phase 2a results: Q3 2017 Partner: Neuropore Partner: Vectura Partner: King s College London neurology immunology
Braine in 5 figures Braine Overview Eric Browaeys Site Director
964 13
54 14
500 15
40 16
1.500.000.000 17
BIO-PILOT GALENIC 18 PROCESS DEVLPT CHEMICAL PACKAGING R&D ADMIN
Green Strategy 19
20 Limit increase global temperature to well below 2 C Reduce CO2 emissions by at least 25% by 2030
CO2 Neutrality by 2075! Potential Scenarios (IPCC) 21 = «as is» = limiting temp rise to 2 C
Impact of Scenarios 22 AS IS 1900 Now : +-1 C + COP21 1900 Now: +- 20cm +
UCB Strategy 23
Scope Scopes 1&2(66 kt) Scope 3 UCB Total footprint : 430 kt (2015 baseline) Neutrality scope: 175 kt (2015 baseline) 24 Our sites Transport Devices &Packaging Suppliers CMOs CARBON NEUTRALITY by 2030 BEST EFFORTS
UCB s 2015 Yearly Emissions = ~ 175 kt of CO2 (excluding CMOs & Suppliers) 25 8% 5% 4% Production sites Business travel (air) 30% Transport - Supply chain (estimated) 12% Fleet (estimated) Key Affiliates (incl Slough) 17% Employee Commuting (estimated) 24% Product end of life (packaging) Waste
UCB Emissions = 1 Airbus A380 in flight 24/24 26
Reduction Milestones 27 120% 100% 80% 95% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 60% 40% 20% 2020 : -5% 2025: -20% 2030: -35% 2050: -70% 30% 0% 2015 2020 2025 2030 2035 2040 2045 2050
Offsetting 28 Forests are Carbon Sinks: 1 Ha = 7 tons CO 2 /year
How? Right Balance between 29 Reduction and Offsetting 80% 20%
CO 2 Agenda to reach Carbon Neutrality by 2030 30 120% 100% 80% 60% 95% 50% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 40% 30% 15% 20% 0% Scopes 1&2 0% 0% 2015 2020 2025 2030 2035 2040 2045 2050-20% Reduction Off setting Total -40% -60% -80% -45% -65% -65% REFORESTATION AVOIDING DEFORESTATION
31 What do we do already? Reduction
32 92% 55% in 2015
1800 33
Cogeneration Principle Annual electrical production : +/- 5,000,000 [kw34h] Annual heat production : +/- 7,000,000 [kwh] CO2 savings : 1,000 tons/year (3% of Braine emissions) Investment: 1,500,000 Operational : Q2 2018 ELECTRICITY 40% HEAT 90% 58%
Global Supply chain ACCOMPLISHMENTS 35 Intermodal Optimization
36
Fleet & Business Travel 37 2.000 1.800 Number of vehicles >< Average CO² levels 1.737 189 200 180 1.600 160 1.400 137 145 140 1.200 1.000 800 600 116 868 120 100 80 60 100% Petrol + EV, HEV, PHEV: 1 January 2018 for BE; 400 200 224 120 40 20 1 June 2018 for UK, DE, NL, US 0 ASIA UCB EUROPE UCB NORTH AMERICA UCB SOUTH AMERICA 0 Vehicle count Average CO2 Value Business Travel: we target a 30% reduction in 2018
Green Teams 38 = Self organized groups of employees located in Braine (8) and HQ working together to reduce their ecological footprint = 1200 Trees / Year for Belgium We will use recycled paper
39 What do we do already? Offsetting
2 projects of Reforestation: Virunga Park, DR Congo Ethiopia 40 280.000 TCO2 by 2030 Partners: WWF CO2 Logic 220.000 T CO2 by 2030 Partners: KUL We Forest Protecting the forests of the Virunga National Park
41 3 billion people in the world are still boiling their water and cooking their food on a fire between 3 stones Using cookstoves could save 50 to 70% of the wood they use and avoid deforestation
Avoid deforestation : Virunga Park, DR Congo 42 410.000 TCO2 by 2030 Partners: WWF CO2 Logic Protecting the forests of the Virunga National Park
1 day UCB = 1 olympic swimming pool 43
100% 44
Our Environmental Commitments by 2030 45-35% - 20% - 25%
Thanks!